You're viewing a sample of the live alert feed. Sign in or create a free account to access the full dashboard.
FDA Approval: KRAZATI (ADAGRASIB) — Type 1 - New Molecular Entity
Oral KRAS inhibitor bills under Part D via specialty pharmacy.
FDA Approval: BYOOVIZ (RANIBIZUMAB-NUNA) — Type 5 - New Formulation or New Manufacturer
Ranibizumab biosimilar BYOOVIZ approved; Part B billing via Q-code expected.
FDA Approval: ETOPOPHOS (ETOPOSIDE PHOSPHATE) — Type 2 - New Active Ingredient
Injectable chemo agent Etopophos bills under Medicare Part B.
FDA Approval: FYARRO (SIROLIMUS) — Type 5 - New Formulation or New Manufacturer
IV sirolimus for rare PEComa tumors bills Part B; verify J-code status.
Sign in to see the full alert feed
From the CLV research desk
Public, source-linked records built from the same pipeline that powers these alerts. Free to read and free to cite.